Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial
dataset
posted on 2024-10-09, 07:01 authored by Gennaro Pagano, Annabelle Monnet, Adriana Reyes, Benjamin Ribba, Hanno Svoboda, Thomas Kustermann, Tanya Simuni, Ronald B. Postuma, Nicola Pavese, Kathrin Brockmann, Fabrizio Stocchi, Krzysztof Smigorski, Valentina Gerbaldo, Paulo Fontoura, Rachelle Doody, Geoffrey A. Kerchner, Patrik Brundin, Kenneth Marek, Azad Bonni, Tania NikolchevaThis exploratory analysis, which requires confirmation in future studies, suggests that the effect of prasinezumab in slowing motor progression in PD may be sustained long-term.
